JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JVI.01483-07v1
81/22/12704    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stanford, M. M.
Right arrow Articles by McFadden, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanford, M. M.
Right arrow Articles by McFadden, G.

 Previous Article  |  Next Article 

Journal of Virology, November 2007, p. 12704-12708, Vol. 81, No. 22
0022-538X/07/$08.00+0     doi:10.1128/JVI.01483-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Myxoma Virus Expressing Human Interleukin-12 Does Not Induce Myxomatosis in European Rabbits{triangledown}

Marianne M. Stanford,1 John W. Barrett,1 Philippe-Alexandre Gilbert,3 Richard Bankert,2 and Grant McFadden3*

Biotherapeutics Research Group, Robarts Research Institute, and Department of Microbiology and Immunology, University of Western Ontario, London, Ontario N6G 2V4, Canada,1 Department of Microbiology, State University of New York, Buffalo, New York 14214,2 Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida 326103

Received 6 July 2007/ Accepted 20 August 2007

Myxoma virus (MV) is a candidate for oncolytic virotherapy due to its ability to selectively infect and kill tumor cells, yet MV is a species-specific pathogen that causes disease only in European rabbits. To assess the ability of MV to deliver cytokines to tumors, we created an MV (vMyxIL-12) that expresses human interleukin-12 (IL-12). vMyxIL-12 replicates similarly to wild-type MV, and virus-infected cells secrete bioactive IL-12. Yet, vMyxIL-12 does not cause myxomatosis, despite expressing the complete repertoire of MV proteins. Thus, vMyxIL-12 exhibits promise as an oncolytic candidate and is safe in all known vertebrate hosts, including lagomorphs.

* Corresponding author. Mailing address: Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610. Phone: (352) 273-6852. Fax: (352) 273-6849. E-mail: grantmcf{at}ufl.edu

{triangledown} Published ahead of print on 29 August 2007.

Journal of Virology, November 2007, p. 12704-12708, Vol. 81, No. 22
0022-538X/07/$08.00+0     doi:10.1128/JVI.01483-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.